Clinical Trials
76
Active:0
Completed:50
Trial Phases
4 Phases
Phase 1:60
Phase 2:9
Phase 3:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (76 trials with phase data)• Click on a phase to view related trials
Phase 1
60 (78.9%)Phase 2
9 (11.8%)Phase 3
4 (5.3%)Not Applicable
3 (3.9%)A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
Not Applicable
Not yet recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: HEC-007 injectionDrug: Placebo
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT07102251
A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
Not Applicable
Not yet recruiting
- Conditions
- Non - Alcoholic Steatohepatitis
- Interventions
- Drug: HEC169584 capsuleDrug: placebo
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT07099118
- Locations
- 🇨🇳
No. 49, Huayuan North Road, Haidian District, Beijing Municipality, Beijing, Beijing, China
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Not Applicable
Not yet recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 472
- Registration Number
- NCT07082842
ADME Study of [14C] Yiqibuvir in Healthy Male Subjects
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05998304
- Locations
- 🇨🇳
Shanghai xuhui central hospital, Shanghai, Shanghai, China
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Phase 3
Not yet recruiting
- Conditions
- Diabetes
- Interventions
- Drug: Insulin Degludec and Insulin Aspart
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT05802862
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next
News
No news found